CHRS

Coherus Oncology, Inc. Healthcare - Biotechnology Investor Relations →

YES
77.5% BELOW
↓ Approaching Was -67.8% last week
-15% -10% -5% 0% 5% 10% 15%+
Signal Threshold $2.34
14-Week RSI 22 📉
Rel. Volume (14w) This week's trading vs. the 14-week average 3.0x — Surging
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 0.69 — Sellers winning

Coherus Oncology, Inc. (CHRS) closed at $0.53 as of 2026-11-13, trading 77.5% below its 200-week moving average of $2.34. This places CHRS in the extreme value zone. The stock is currently moving closer to the line, down from -67.8% last week. With a 14-week RSI of 22, CHRS is in oversold territory.

A big spike in selling this week — 3.0x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.

Over the past 579 weeks of data, CHRS has crossed below its 200-week moving average 11 times. On average, these episodes lasted 41 weeks. The average one-year return after crossing below was -3.5%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $81 million, CHRS is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -275.2%. The stock trades at 3.2x book value.

Share count has increased 53.6% over three years, indicating dilution.

Over the past 11.2 years, a hypothetical investment of $100 in CHRS would have grown to $2, compared to $434 for the S&P 500. CHRS has returned -29.9% annualized vs 14.0% for the index, underperforming the broader market over this period.

Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: CHRS vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After CHRS Crosses Below the Line?

Across 11 historical episodes, buying CHRS when it crossed below its 200-week moving average produced an average return of -14.5% after 12 months (median -12.0%), compared to +15.8% for the S&P 500 over the same periods. 27% of those episodes were profitable after one year. After 24 months, the average return was -40.9% vs +37.7% for the index.

Each line shows $100 invested at the moment CHRS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Dislocation Scores Experimental

Each score measures deviation from CHRS's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation N/A Dividend yield vs own 10-yr norm
Drawdown Score +1.28σ Distance from line vs own history
Sector-Relative +0.83σ Vs sector median this week
Buyback Acceleration -10.6pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History -125.7pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+645.9pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Historical Touches

CHRS has crossed below its 200-week MA 11 times with an average 1-year return of +-3.5% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Oct 2015Oct 201510.4%+23.6%-97.9%
Dec 2015Jul 20163145.8%+14.5%-97.9%
Feb 2017May 201911862.4%-59.4%-97.7%
Jun 2019Jun 201912.2%+5.1%-97.1%
Jul 2019Jul 201927.4%+4.5%-97.0%
Oct 2019Oct 201914.3%+4.2%-96.9%
Dec 2019Jan 202021.2%-1.0%-97.0%
Mar 2020May 20201121.8%+8.7%-96.5%
Jun 2020Jun 202037.9%-9.8%-96.7%
Mar 2021Sep 20212817.7%-25.1%-96.7%
Dec 2021Ongoing255+91.4%Ongoing-96.7%
Average41—+-3.5%—

Frequently Asked Questions

Is CHRS below its 200-week moving average?

Yes. As of 2026-11-13, Coherus Oncology, Inc. (CHRS) is trading 77.5% below its 200-week moving average of $2.34. The current price is $0.53.

What is CHRS's 200-week moving average price?

Coherus Oncology, Inc.'s 200-week moving average is $2.34 as of 2026-11-13. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when CHRS drops below its 200-week moving average?

CHRS has crossed below its 200-week moving average 11 times in our data. The average one-year return after these crossings was -3.5%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 41 weeks on average.

Is CHRS a good value right now?

Here's what our data says about CHRS as of 2026-11-13: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 22 (oversold). Free cash flow is currently negative. Return on equity is -275.2%. Price-to-book is 3.2x. This is not a buy or sell recommendation — always do your own research.

How does CHRS compare to the S&P 500?

Over the past 11.2 years, $100 invested in CHRS would have grown to $2, compared to $434 for the S&P 500. That's -29.9% annualized vs 14.0% for the index. CHRS has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-11-13